Abstract
Antisense oligonucleotides (ASOs) are a well-established therapeutic modality based on RNA interference, but low cellular uptake, limited ability to direct ASO trafficking, and a range of intracellular barriers to successful activity compromise both gene silencing outcomes and clinical translations. Herein, we demonstrate that polymers can increase ASO internalisation via intracellular trafficking pathways that are distinct from lipid-based delivery reagents. For the first time, we spatially define internalisation and dissociation stages in the polymer-mediated cytosolic delivery of ASOs using Nanoscale Secondary Ion Mass Spectrometry (NanoSIMS), which enables visualisation of ASO localisation at the organelle level. We find that polymer-ASO complexes are imported into cells, from which free ASO enters the cytosol following complex dissociation. This information enables a better understanding of the intracellular trafficking pathways of nucleic acid therapeutics and may be exploited for therapeutic delivery to enhance the effectiveness of nucleic acid therapeutics in the future.
Introduction
Antisense oligonucleotides (ASOs) are powerful tools for precision medicine, designed to "turn off" specific genes by intercepting mRNA. However, their therapeutic potential is often limited by the logistical challenge of cellular entry. As large, negatively charged molecules, ASOs do not readily cross lipophilic cell membranes. While delivery vehicles like cationic polymers and lipids are employed to facilitate this process, the exact mechanisms of intracellular release have remained poorly understood—a "black box" in drug delivery.
Methodology: Correlative Electron and Ion Microscopy
To visualize these interactions at the sub-organelle level, researchers utilized Correlative Electron and Ion Microscopy (CEIM), which integrates the structural detail of Scanning Electron Microscopy (SEM) with the chemical sensitivity of Nanoscale Secondary Ion Mass Spectrometry (NanoSIMS).
A key innovation in this study was the use of dual isotopic labeling. Instead of bulky fluorescent dyes, the team used stable isotopes as "stealth" tags: Iodine ($^{127}I$) for the ASO and Bromine ($^{79}Br$) for the dendronized polymer carrier. NanoSIMS allows for chemical mapping with a lateral resolution of ~40 nm, well below the diffraction limit of light, enabling the tracking of these molecules without altering their biological behavior.
Results: Potency and Uptake Efficiency
The polymer delivery system significantly enhanced ASO performance. Quantitative analysis revealed that the polymer-mediated delivery achieved an $IC_{50}$ for MALAT1 knockdown of 0.298 nM, making it nearly 86 times more potent than free ASO uptake (25.64 nM).
Flow cytometry confirmed high efficiency, with polymer-mediated delivery reaching over 98% transfection efficiency within 6 hours, comparable to the lipid-based reagent Lipofectamine RNAiMAX.
Visualizing the Dissociation Stage
The most significant insight provided by NanoSIMS was the spatial definition of the dissociation stage. The images captured the moment the ASO "breaks free" from its polymer vehicle. Within sulfur-rich endolysosomal compartments, the Iodine (ASO) and Bromine (polymer) signals were observed to offset, marking the first time ASO release from a polymer has been visualized at this scale.
Furthermore, the study highlighted that the pathway of entry is more critical than the total payload. While cells treated with free ASOs showed high total internal accumulation, they exhibited much lower gene-silencing activity. This suggests that polymers shepherd ASOs into specific endolysosomal "waiting rooms" that facilitate more productive cytosolic escape compared to the random pathways of free uptake.
Conclusion
This work demonstrates that polymers facilitate a distinct intracellular trafficking pathway compared to traditional lipid-based reagents. By quantifying the transition from complexed to free ASO, researchers can now screen and fine-tune polymer designs to optimize release kinetics, paving the way for more effective nucleic acid-based therapies.
Summary updated